The FDA approval is a near term catalyst that will take NVAX stock to new highs over the coming months. Buy NVAX stock in the dip. More
Articles
Even in the ‘New Normal’, Zoom Video Stock Looks Like a Buy Under $275
Despite Zoom Video calling off its $14.7-billion merger at the end of September, ZM stock has managed to push higher. Is it a buy here? More
ADA-USD: Cardano Is Facing a Technical Make-or-Break Moment
If Cardano is to move higher, it’s got to break out of ADA-USD's consolidation pattern now since its underlying fundamentals won’t help. More
Emotional Perceptions Shouldn’t Drive Your Carnival Stock Decision
All things considered, Carnival stock has been a great investment since the beginning of the pandemic. But with bookings rising are emotions driving sentiment in CCL stock? More
If China’s Tech Crackdown Has Peaked, DiDi Global Stock Is Now Cheap
DiDi Global now sells at par to next year's expected revenue. If it can get past China's tech crackdown, it's a cheap stock. More
QuantumScape Stock Is a Tough Buy, but It May Be a Tougher Sell
Analysts are sharply divided on QS stock, so investors will have to trust their gut on this pre-revenue company. More
